Study to Compare Mediterranean vs. HP/LC Diets on Arterial Stiffness in Obese Semaglutide Users

Obesity is a major risk factor for cardiovascular disease (CVD), often leading to increased arterial stiffness and accumulation of visceral adipose tissue (VAT). These factors independently predict adverse CV events. While Semaglutide effectively promotes weight loss and improves metabolic parameters, its specific impact on arterial stiffness and VAT in conjunction with different dietary patterns remains less explored. Current dietary guidelines for obese patients are broad, and understanding how specific diets like the Mediterranean diet or high protein/low carbohydrate (HP/LC) diet modulate Semaglutide's benefits on CV health is crucial for optimized patient care.

Researchers plan to conduct a study comparing the effects of two distinct dietary interventions—the Mediterranean diet and a high protein/low carbohydrate (HP/LC) diet—in obese patients initiating Semaglutide for weight management. The primary objective is to assess changes in cardiovascular (CV) parameters, specifically arterial stiffness measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue (VAT). The study will also evaluate other metabolic indicators to provide a comprehensive understanding of dietary impacts alongside Semaglutide therapy.